Sam Altman, AI and Retro Biosciences

Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan
Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT reports.
Sam Altman-backed AI biotech announces $1 billion for its lofty goal: adding 10 years to human life span
Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.
Sam Altman reportedly backs $1B round for AI healthcare startup Retro Biosciences
Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in funding to support its research. The Financial Times today cited sources as saying that Sam Altman is participating in the investment. He previously provided the initial $180 million funding round that helped launch Retro.
Sam Altman-backed start-up is raising $1B to extend human lifespan
OpenAI CEO Sam Altman backs Retro Biosciences, a San Francisco-based biotech start-up that wants to extend human lifespan by 10 years beyond what it describes as a healthy lifespan. The company is now raising $1 billion in a Series A funding round, with Altman participating.
With Sam Alt­man’s help, Retro Bio­sciences eyes $1B to ex­tend lifes­pan by 10 years
Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed in a Friday email to Endpoints News.
The Prototype: OpenAI And Retro Biosciences Made An AI Model For Bioengineering
Plus: Blue Origin and SpaceX launch big rockets, how magnets could guide lasers to make better computers, how to best work ...
AI tracker: AI at the Maha Kumbh, and in longevity science
We saw several innovative uses of AI in the past week, and a bad slip-up in news sharing. A quick round-up: ...
MIT Technology Review9d
OpenAI has created an AI model for longevity science
OpenAI’s new model, called GPT-4b micro, was trained to suggest ways to re-engineer the protein factors to increase their ...
Sam Altman-Backed Retro Biosciences Raising $1 Billion to Extend Human Lifespan
Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...